Attached files
| file | filename |
|---|---|
| 8-K/A - 8-K/A - Larimar Therapeutics, Inc. | d947173d8ka.htm |
| EX-99.5 - EX-99.5 - Larimar Therapeutics, Inc. | d947173dex995.htm |
| EX-99.4 - EX-99.4 - Larimar Therapeutics, Inc. | d947173dex994.htm |
| EX-99.3 - EX-99.3 - Larimar Therapeutics, Inc. | d947173dex993.htm |
| EX-99.2 - EX-99.2 - Larimar Therapeutics, Inc. | d947173dex992.htm |
| EX-99.1 - EX-99.1 - Larimar Therapeutics, Inc. | d947173dex991.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-196900, 333-204931, 333-210216, 333-216602, 333-223561, 333-230291, 333-234579, 333-236917, and 333-228326) and Form S-3 (Nos. 333-219834 and 333-228328) of Larimar Therapeutics, Inc. of our report dated March 6, 2020 relating to the financial statements of Chondrial Therapeutics, Inc., which appears in this Current Report on Form 8-K/A.
/s/ PricewaterhouseCoopers LLP
Philadelphia, Pennsylvania
June 26, 2020